Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells
Version of Record online: 30 APR 2014
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Journal of Cellular and Molecular Medicine
Volume 18, Issue 7, pages 1392–1406, July 2014
How to Cite
Zhang, F., Zhang, Z., Chen, L., Kong, D., Zhang, X., Lu, C., Lu, Y. and Zheng, S. (2014), Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells. Journal of Cellular and Molecular Medicine, 18: 1392–1406. doi: 10.1111/jcmm.12286
- Issue online: 30 JUL 2014
- Version of Record online: 30 APR 2014
- Manuscript Accepted: 17 FEB 2014
- Manuscript Received: 2 NOV 2013
- National Natural Science Foundation of China. Grant Numbers: 81270514, 30873424
- Doctoral Discipline Foundation of the Ministry of Education of China. Grant Number: 20103237110010
- Project for Supporting Jiangsu Provincial Talents in Six Fields. Grant Number: 2009-B-010
- Youth Natural Science Foundation of Nanjing University of Chinese Medicine. Grant Number: 13XZR20
- “Eleven-Five” National Science and Technology Supporting Program. Grant Number: 2008BAI51B02
|jcmm12286-sup-0001-FigS1.tif||image/tif||25K||Figure S1 Curcumin reduces liver/body weight ratio in rat fibrotic liver caused by CCl4. Rats were grouped: group 1, vehicle control (no CCl4, no treatment); group 2, model group (with CCl4, no treatment); group 3, curcumin-treated group (100 mg/kg + CCl4); group 4, curcumin-treated group (200 mg/kg + CCl4); group 5, curcumin-treated group (400 mg/kg + CCl4). #P < 0.05 versus group 1, *P < 0.05 versus group 2, n = 6.|
|jcmm12286-sup-0002-FigS2.tif||image/tif||57K||Figure S2 Effects of curcumin (A), imatinib (B), U0126 (C) and rapamycin (D) on cell viability in HSCs. HSCs were treated with DMSO (0.02%, w/v) and compounds at indicated concentrations for 24 hrs. Cell viability was evaluated by MTS assay. For the statistics of each panel in this figure, *P < 0.05 versus control.|
|jcmm12286-sup-0003-FigS3.tif||image/tif||38K||Figure S3 Effects of Y15 (A) and fasudil (B) on cell viability in HSCs. HSCs were treated with DMSO (0.02%, w/v) and compounds at indicated concentrations for 24 hrs. Cell viability was evaluated by MTS assay. For the statistics of each panel in this figure, *P < 0.05 versus control.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.